77.93  -3.52 (-4.32%)		07-10 16:00
Open: 80.59 High: 80.825 Volume: 1,166,343		Pre. Close: 81.45 Low: 76.15 Market Cap: 6,930(M)

Short term
Mid term
Targets	6-month :	96.89	1-year :	113.17
Resists	First :	82.95	Second :	96.89
Pivot price	77.57
Supports	First :	65.37	Second :	54.5
MAs	MA(5) :	79.85	MA(20) :	75.74
	MA(100) :	49.66	MA(250) :	37
MACD	MACD :	4.9	Signal :	5.4
%K %D	K(14,3) :	79.3	D(3) :	84.8
RSI	RSI(14): 60.7
52-week	High :	82.95	Low :	13.88

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ LQDA ] has closed below upper band by 46.8%. Bollinger Bands are 17.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	80.94 - 81.35	81.35 - 81.69
Low:	75.24 - 75.66	75.66 - 76
Close:	77.31 - 77.97	77.97 - 78.52

Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.

Fri, 10 Jul 2026
Is Liquidia Corp (LQDA) a Bargain After 4.3% Drop? GF Value Says Undervalued - GuruFocus

Fri, 10 Jul 2026
Did Liquidia’s (LQDA) Russell Index Exit Just Reframe Its Pulmonary Hypertension Investment Narrative? - simplywall.st

Wed, 08 Jul 2026
[Form 4] Liquidia Corp Insider Trading Activity - Stock Titan

Wed, 08 Jul 2026
BlackRock (LQDA) discloses 10.55M shares, 11.9% stake in LIQUIDIA - Stock Titan

Tue, 07 Jul 2026
LQDA Stock Soars 129.7% YTD: Is There More Room for Growth? - Yahoo Finance

Mon, 06 Jul 2026
Fund tied to Liquidia (LQDA) director sells 25K common shares - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	89 (M)
Held by Insiders	6.266e+007 (%)
Held by Institutions	12.7 (%)
Shares Short	10,210 (K)
Shares Short P.Month	0 (K)

EPS	4.663e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	7.7 %
Operating Margin	46.2 %
Return on Assets (ttm)	9 %
Return on Equity (ttm)	28.1 %
Qtrly Rev. Growth	4 %
Gross Profit (p.s.)	268.64
Sales Per Share	4.88237e+008
EBITDA (p.s.)	4.48288e+008
Qtrly Earnings Growth	0.1 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	48 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	37.38

Dividend	0
Forward Dividend	1.161e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.